TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY
6.1. Overview
6.2. Immunocytokines
6.3. Immunotoxins
6.4. Radioisotope Immunoconjugates
7. GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION
7.1. Overview
7.2. Acute Myeloid Leukemia
7.3. Bladder Cancer
7.4. Diffuse Large B-cell Lymphoma
7.5. Graft-versus-host disease
7.6. Melanoma Prostate Cancer
7.7. Soft-tissue Sarcoma
8. GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY
8.1. Overview
8.2. Combination Therapy
8.3. Monotherapy
9. GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
9.1. Overview
9.2. Intratumoral
9.3. Intravenous
9.4. Intravesical
10. GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY REGION
10.1. Overview
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. France
10.2.3. UK
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Australia
10.3.6. Rest of Asia-Pacific
10.4. Rest of the World
10.4.1. Middle East
10.4.2. Africa
10.4.3. Latin America
11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the Global Next-Generation Antibody Therapeutics Market,
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Global Next-Generation Antibody Therapeutics Market,
11.7. Key developments and Growth Strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales & Operating Income, 2023
11.8.2. Major Players R&D Expenditure. 2023
12. COMPANY PROFILES
12.1. Genmab A/S
12.1.1. Company Overview
12.1.2. Financial Overview
12.1.3. Products Offered
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Seattle Genetics, Inc.
12.2.1. Company Overview
12.2.2. Financial Overview
12.2.3. Products Offered
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Immunomedics, Inc.
12.3.1. Company Overview
12.3.2. Financial Overview
12.3.3. Products Offered
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. Daiichi Sankyo Company, Limited
12.4.1. Company Overview
12.4.2. Financial Overview
12.4.3. Products Offered
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Immunocore Limited
12.5.1. Company Overview
12.5.2. Financial Overview
12.5.3. Products Offered
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. Zymeworks Inc.
12.6.1. Company Overview
12.6.2. Financial Overview
12.6.3. Products Offered
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. AstraZeneca PLC
12.7.1. Company Overview
12.7.2. Financial Overview
12.7.3. Products Offered
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. BRISTOL MYERS SQUIBB COMPANY
12.8.1. Company Overview
12.8.2. Financial Overview
12.8.3. Products Offered
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. Roche Holding AG
12.9.1. Company Overview
12.9.2. Financial Overview
12.9.3. Products Offered
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. AMGEN INC.
12.10.1. Company Overview
12.10.2. Financial Overview
12.10.3. Products Offered
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 6 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 9 NORTH AMERICA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 10 NORTH AMERICA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 11 US: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 12 US: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 13 US: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 14 US: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 15 CANADA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 16 CANADA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 17 CANADA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 18 CANADA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 19 EUROPE: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 20 EUROPE: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 21 EUROPE: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 22 EUROPE: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 23 GERMANY: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 24 GERMANY: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 25 GERMANY: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 26 GERMANY: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 27 FRANCE: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 28 FRANCE: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 29 FRANCE: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 30 FRANCE: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 31 ITALY: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 32 ITALY: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 33 ITALY: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 34 ITALY: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 35 SPAIN: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 36 SPAIN: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 37 SPAIN: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 38 SPAIN: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 39 UK: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 40 UK: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 41 UK: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 42 UK: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 43 REST OF EUROPE: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 44 REST OF EUROPE: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 45 REST OF EUROPE: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 46 REST OF EUROPE: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 47 ASIA-PACIFIC: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 48 ASIA-PACIFIC: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 49 ASIA-PACIFIC: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 50 ASIA-PACIFIC: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 51 JAPAN: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 52 JAPAN: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 53 JAPAN: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 54 JAPAN: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 55 CHINA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 56 CHINA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 57 CHINA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 58 CHINA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 59 INDIA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 60 INDIA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 61 INDIA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 62 INDIA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 63 AUSTRALIA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 64 AUSTRALIA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 65 AUSTRALIA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 66 AUSTRALIA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 67 SOUTH KOREA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 68 SOUTH KOREA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 69 SOUTH KOREA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 70 SOUTH KOREA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 71 REST OF ASIA-PACIFIC: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 72 REST OF ASIA-PACIFIC: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 73 REST OF ASIA-PACIFIC: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 74 REST OF ASIA-PACIFIC: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 75 REST OF THE WORLD: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 76 REST OF THE WORLD: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 77 REST OF THE WORLD: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 78 REST OF THE WORLD: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 79 MIDDLE EAST: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 80 MIDDLE EAST: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 81 MIDDLE EAST: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 82 MIDDLE EAST: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 83 AFRICA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 84 AFRICA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 85 AFRICA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 86 AFRICA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 87 LATIN AMERICA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF NOVEL ANTIBODY, 2019-2032 (USD BILLION)
TABLE 88 LATIN AMERICA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TARGET INDICATION, 2019-2032 (USD BILLION)
TABLE 89 LATIN AMERICA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TYPE OF THERAPY, 2019-2032 (USD BILLION)
TABLE 90 LATIN AMERICA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET
FIGURE 4 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, SHARE (%), BY TYPE OF NOVEL ANTIBODY, 2023
FIGURE 5 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, SHARE (%), BY TARGET INDICATION, 2023
FIGURE 6 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, SHARE (%), BY TYPE OF THERAPY, 2023
FIGURE 7 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, SHARE (%), BY ROUTE OF ADMINISTRATION, 2023
FIGURE 8 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, SHARE (%), BY REGION, 2023
FIGURE 9 NORTH AMERICA: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, SHARE (%), BY REGION, 2023
FIGURE 10 EUROPE: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, SHARE (%), BY REGION, 2023
FIGURE 11 ASIA-PACIFIC: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, SHARE (%), BY REGION, 2023
FIGURE 12 REST OF THE WORLD: NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, SHARE (%), BY REGION, 2023
FIGURE 13 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 14 GENMAB A/S: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 GENMAB A/S: SWOT ANALYSIS
FIGURE 16 SEATTLE GENETICS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 SEATTLE GENETICS, INC.: SWOT ANALYSIS
FIGURE 18 IMMUNOMEDICS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 IMMUNOMEDICS, INC.: SWOT ANALYSIS
FIGURE 20 DAIICHI SANKYO COMPANY, LIMITED: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 DAIICHI SANKYO COMPANY, LIMITED: SWOT ANALYSIS
FIGURE 22 IMMUNOCORE LIMITED.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 IMMUNOCORE LIMITED.: SWOT ANALYSIS
FIGURE 24 ZYMEWORKS INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 ZYMEWORKS INC.: SWOT ANALYSIS
FIGURE 26 ASTRAZENECA PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 ASTRAZENECA PLC: SWOT ANALYSIS
FIGURE 28 BRISTOL MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 BRISTOL MYERS SQUIBB COMPANY: SWOT ANALYSIS
FIGURE 30 ROCHE HOLDING AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 ROCHE HOLDING AG: SWOT ANALYSIS
FIGURE 32 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 AMGEN INC.: SWOT ANALYSIS
